

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – April 11, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. March 14, 2012 DUR Minutes – Vote
 - B. March 15, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for December 2011
 - B. Retrospective Drug Utilization Review Response for October 2011
 - C. Medication Coverage Activity for March 2012

Items to be presented by Dr. Martinez, Dr. Muchmore, Chairman

- 5. Genetic Technologies in Health Care – Presented by Alison Adams Martinez, Ph.D., OHCA Clinical Data Analyst**

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 6. Action Item – Vote to Prior Authorize Kalydeco™ – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Growth Hormones – See Appendix D.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

8. **FY 2011 Annual Review – See Appendix E.**
 - A. Top 100 Medications by Total Pharmacy Reimbursement
 - B. Top 50 Medications by Number of Pharmacy Claims
 - C. Pharmacy Claims Comparison by Therapeutic Category

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Questions Regarding Annual Review of Requip XL[®] and Mirapex ER[®] – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **Action Item – Questions Regarding Annual Review of Metazolol[®] – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix H.**
12. **Future Business**
 - A. Annual Review of Atypical Antipsychotics
 - B. Annual Review of NSAIDs
 - C. New Product Reviews
 - D. Medical Product Reviews

13. **Adjournment**